Evidence map›Paper›PMID 24510238›Full record

ArticleCarcinogenesis2014

Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer.

Yekaterina Y Zaytseva, Victoria A Elliott, Piotr Rychahou, W Conan Mustain, Ji Tae Kim, Joseph Valentino, Tianyan Gao, Kathleen L O'Connor, Janna M Neltner, Eun Y Lee and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Carcinogenesis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 104 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yekaterina Y ZaytsevaMarkey Cancer Center.
Victoria A ElliottMarkey Cancer Center.
Piotr RychahouMarkey Cancer Center, Department of Surgery.
W Conan MustainDepartment of Surgery.
Ji Tae KimMarkey Cancer Center, Department of Surgery.
Joseph ValentinoDepartment of Surgery.
Tianyan GaoDepartment of Molecular and Cellular Biochemistry.
Kathleen L O'ConnorMarkey Cancer Center.
Janna M NeltnerDepartment of Pathology and Laboratory Medicine and.
Eun Y LeeMarkey Cancer Center, Department of Surgery, Department of Pathology and Laboratory Medicine and.
Heidi L WeissMarkey Cancer Center, Department of Biostatistics, University of Kentucky, Lexington, KY 40536, USA.
B Mark EversMarkey Cancer Center, Department of Surgery, mark.evers@uky.edu.
Markey Cancer Center · US

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI KATHLEEN L. O'CONNOR · 2013 to 2026
$38.3M
SURGICAL STUDIES OF FUNCTIONAL GENE EXPRESSIONR01DK048498 · NIDDK · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI EVERS, BERNARD MARK · 1996 to 2023
$7.9M
The Role of PHLPP in Colon CancerR01CA133429 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GAO, TIANYAN · 2009 to 2024
$5.6M
Interdisciplinary Research Training in Cancer BiologyT32CA165990 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers, KATHLEEN L. O'CONNOR · 2013 to 2026
$3.2M
Novel Mechanisms of Carcinoma Cell MigrationR01CA109136 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI O'CONNOR, KATHLEEN L. · 2006 to 2016
$2.6M
UK SPORE in Gastrointestinal CancerP20CA150343 · NCI · UNIVERSITY OF KENTUCKY · PI EVERS, BERNARD MARK · 2009 to 2011
$1.5M
NCI NIH HHS P20 CA150343NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA109136NCI NIH HHS R01 CA133429NCI NIH HHS T32 CA165990NIDDK NIH HHS R01 DK048498
6 · The paper itself

Abstract

Upregulation of fatty acid synthase (FASN), a key enzyme of de novo lipogenesis, is associated with metastasis in colorectal cancer (CRC). However, the mechanisms of regulation are unknown. Since angiogenesis is crucial for metastasis, we investigated the role of FASN in the neovascularization of CRC. The effect of FASN on tumor vasculature was studied in orthotopic CRCs, the chick embryo chorioallantoic membrane (CAM) and Matrigel plug models using immunohistochemistry, immunofluorescent staining and confocal microscopy. Cell secretion was evaluated by ELISA and antibody arrays. Proliferation, migration and tubulogenesis of endothelial cells (ECs) were assessed in CRC-EC coculture models. In this study, we found that stable knockdown of FASN decreased microvessel density in HT29 and HCT116 orthotopic CRCs and resulted in 'normalization' of tumor vasculature in both orthotopic and CAM models. Furthermore, FASN regulated secretion of pro- and antiangiogenic factors, including vascular endothelial growth factor-A (VEGF-A). Mechanisms associated with the antiangiogenic activity noted with knockdown of FASN included: downregulation of VEGF(189), upregulation of antiangiogenic isoform VEGF(165b) and a decrease in expression and activity of matrix metalloproteinase-9. Furthermore, conditioned medium from FASN knockdown CRC cells inhibited activation of vascular endothelial growth factor receptor-2 and its downstream signaling and decreased proliferation, migration and tubulogenesis of ECs as compared with control medium. Together, these results suggest that cancer cell-associated FASN regulates tumor vasculature through alteration of the profile of secreted angiogenic factors and regulation of their bioavailability. Inhibition of FASN upstream of VEGF-A and other angiogenic pathways can be a novel therapeutic strategy to prevent or inhibit metastasis in CRC.

Indexed as

AnimalsCell Line, TumorChick EmbryoColorectal NeoplasmsDisease Models, AnimalEndothelial CellsFatty Acid SynthasesGene Expression RegulationGene Knockdown TechniquesHeterograftsHumansMaleMatrix Metalloproteinase 9Neovascularization, PathologicSignal TransductionVascular Endothelial Growth Factor AFatty Acid SynthasesMatrix Metalloproteinase 9Vascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID24510238
PMCPMC4043242
OpenAlexW2135805794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.